Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Ardelyx Inc

ARDX
Current price
4.76 USD +0.26 USD (+5.78%)
Last closed 4.51 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 104 976 896 USD
Yield for 12 month +155.91 %
Week
Month
Year
ARDX
21.11.2021 - 28.11.2021

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Address: 400 Fifth Avenue, Waltham, MA, United States, 02451

Analytics

WallStreet Target Price

10.31 USD

P/E ratio

Dividend Yield

Current Year

+52 158 000 USD

Last Year

+10 097 000 USD

Current Quarter

+56 391 000 USD

Last Quarter

+22 333 000 USD

Current Year

+48 041 000 USD

Last Year

+9 097 000 USD

Current Quarter

+49 343 000 USD

Last Quarter

+18 844 000 USD

Key Figures ARDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -15 890 000 USD
Operating Margin TTM 13.12 %
PE Ratio
Return On Assets TTM -4.88 %
PEG Ratio -0.08
Return On Equity TTM -20.59 %
Wall Street Target Price 10.31 USD
Revenue TTM 134 271 008 USD
Book Value 0.82 USD
Revenue Per Share TTM 0.64 USD
Dividend Share
Quarterly Revenue Growth YOY 1031 %
Dividend Yield
Gross Profit TTM 15 540 000 USD
Earnings Share -0.06 USD
Diluted Eps TTM -0.06 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -19.79 %

Dividend Analytics ARDX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ARDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 7.2565
Price Sales TTM 8.2295
Enterprise Value EBITDA -55.9736
Price Book MRQ 5.7803

Financials ARDX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ARDX

For 52 weeks

1.7 USD 5.13 USD
50 Day MA 3.93 USD
Shares Short Prior Month 36 472 608
200 Day MA 3.94 USD
Short Ratio 4.55
Shares Short 38 122 169
Short Percent 16.7 %